v3.26.3
Condensed Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2024 $ 44 $ 30,194,093 $ (26,022,129) $ 4,172,008
Balance, shares at Dec. 31, 2024 441,385      
Stock-based compensation 1,676,667 1,676,667
Related-party forgiveness of accrued compensation      
Net loss (6,069,866) (6,069,866)
Shares issued for services rendered 66,000 66,000
Shares issued for services rendered, shares 1,376      
Reverse stock split rounding adjustment $ 1 (1)
Shares issued for warrant exercises $ 1 (1)
Shares issued for warrant exercises, shares 12,585      
Shares issued in connection with warrant amendments 212,608 212,608
Shares issued in connection with warrant amendments, shares 1,915      
Balance at Sep. 30, 2025 $ 46 32,149,366 (32,091,995) 57,417
Balance, shares at Sep. 30, 2025 457,261      
Balance at Jun. 30, 2025 $ 46 31,144,033 (29,803,961) 1,340,118
Balance, shares at Jun. 30, 2025 464,441      
Stock-based compensation 792,725 792,725
Net loss (2,288,034) (2,288,034)
Reverse stock split rounding adjustment 1 (1)
Shares issued for warrant exercises $ 1 (1)
Shares issued for warrant exercises, shares 12,585      
Shares issued in connection with warrant amendments 212,608 212,608
Shares issued in connection with warrant amendments, shares 1,915      
Shares not issued for vested restricted stock units due to administrative delay – See Note 7 $ (2) 2
Shares not issued for vested restricted stock units due to administrative delay, shares (21,680)      
Balance at Sep. 30, 2025 $ 46 32,149,366 (32,091,995) 57,417
Balance, shares at Sep. 30, 2025 457,261      
Balance at Dec. 31, 2025 $ 46 32,835,128 (34,667,026) (1,831,852)
Balance, shares at Dec. 31, 2025 459,286      
Stock-based compensation   1,497,113 1,497,113
Shares issued under license agreement $ 13 889,465 889,478
Shares issued under PharmAla license agreement, shares 132,867      
Issuance of common stock for payment of notes and interest $ 28 5,001,568 5,001,596
Issuance of common stock for payment of notes and interest, shares 277,141      
SEPA shares sold for cash proceeds $ 1 87,054 87,055
SEPA shares sold for cash proceeds, shares 13,466      
Registered direct offering, net of 7% offering costs $ 41 3,719,957 3,719,998
Registered direct offering, net of placement fees, shares 402,930      
Related-party forgiveness of accrued compensation 875,315 875,315
Net loss (11,560,425) (11,560,425)
Shares issued for exercise of stock options $ 1 5,506 $ 5,507
Shares issued for exercise of stock options, shares 9,000     9,000
Shares issued for conversion of convertible notes 107,463 $ 107,463
Shares issued for conversion of convertible notes, shares 1,519      
Shares issued for services rendered 46,750 46,750
Shares issued for services rendered, shares 667      
RSU Conversions $ 2 (2)
RSU Conversions, shares 21,680      
Reverse stock split rounding adjustment
Reverse stock split rounding adjustment, shares (35)      
Balance at Sep. 30, 2026 $ 132 45,065,317 (46,227,451) (1,162,002)
Balance, shares at Sep. 30, 2026 1,318,521      
Balance at Jun. 30, 2026 $ 66 38,637,349 (39,003,381) (365,966)
Balance, shares at Jun. 30, 2026 664,670      
Stock-based compensation 551,874 551,874
Shares issued under license agreement $ 13 889,465 889,478
Shares issued under PharmAla license agreement, shares 132,867      
Issuance of common stock for payment of notes and interest $ 21 2,164,293 2,164,314
Issuance of common stock for payment of notes and interest, shares 199,861      
SEPA shares sold for cash proceeds $ 1 87,054 87,055
SEPA shares sold for cash proceeds, shares 13,466      
Reverse stock split rounding adjustment    
Equity adjustments and rounding, shares $ (35)      
Registered direct offering, net of 7% offering costs $ 31 1,859,967 1,859,998
Registered direct offering, net of placement fees, shares 307,692      
Related-party forgiveness of accrued compensation 875,315   875,315
Net loss     (7,224,070) (7,224,070)
Balance at Sep. 30, 2026 $ 132 $ 45,065,317 $ (46,227,451) $ (1,162,002)
Balance, shares at Sep. 30, 2026 1,318,521